NeuroVasc Technologies Announces First Patient Treated in Clinical Trial to Evaluate Its Novel Stent-Retriever

NeuroVasc Technologies, Inc. today announced that the first patient has been treated in its US IDE Clinical Trial, ENVI RCT – NeuroVasc Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke. This trial will evaluate the safety and efficacy of the NeuroVasc ENVI™-SR, a stent-retriever intended for the treatment of acute ischemic stroke to reduce disability by removing blood clots in patients with stroke due to large vessel occlusion.

“By enrolling this first patient in this trial, we’re taking an important step toward building evidence to support the clinical use of this novel, next generation stroke device,” shared Vitor Mendes Pereira, MD, a neurosurgeon with St. Michael’s Hospital, University of Toronto, who is a co-Principal Investor along with Raul Nogueira, MD, director of the University of Pittsburgh Medical Center (UPMC) Stroke Institute and professor of neurology at UPMC.

The study is a prospective, multinational, randomized, parallel group-controlled, blinded, non-inferiority trial to examine and compare clinical outcomes of patients being treated for acute ischemic stroke, as measured by Modified Rankin Scale (mRS) at 90 days post treatment, and related performance characteristics of the NeuroVasc ENVI™-SR and concurrent parallel Control Devices currently cleared by the U.S. FDA for treatment of ischemic stroke.

“We are very proud to be participating in such trials to further advance the treatment we can offer to our patients,” said Nima Amin Aghaebrahim, MD, interventional neurologist and primary stroke director at Baptist Stroke & Cerebrovascular Center in Jacksonville, Florida, who performed the procedure.

The study will compare the next generation NeuroVasc ENVI™-SR with the Solitaire™ (Medtronic) and Trevo® (Stryker) product families.

“Partnering with the neurointerventional community in the U.S. offers us a great opportunity to investigate our novel technology with the view to improving the treatment of patients experiencing acute ischemic stroke around the world. We are proud of the NeuroVasc team in reaching this milestone,” said Michael Losordo, NeuroVasc chief operating officer.

As populations age, the number of strokes is also on the rise. According to the World Health Organization, stroke is the second leading cause of death worldwide. An acute ischemic stroke occurs when the blood supply to part of the brain is interrupted or reduced, preventing brain tissue from getting oxygen and nutrients. When that happens, brain cells begin to die in minutes and prompt treatment is crucial. Early action can reduce brain damage and potential outcomes such as physical disability and death.

“We are glad to get started on another landmark study, helping to bring new technology to our region and country,” said Ricardo Hanel, MD, PhD, neurosurgeon and co-medical director of Baptist Stroke & Cerebrovascular Center.

The results of the study will support an application to the U.S. FDA for clearance of the NeuroVasc ENVI™-SR device in the US, further expanding our commercial footprint and providing a strong foundation for NeuroVasc’s future pipeline of game-changing neurovascular technologies.

About the ENVI RCT – NeuroVasc Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke: The ENVI RCT trial is the first prospective clinical trial in Ischemic Stroke which is an international, multicenter, randomized, controlled clinical trial to assess the effectiveness and safety of the NeuroVasc Envi™-SR mechanical thrombectomy device for the restoration of blood flow in ischemic stroke. The trial is planned to enroll approximately 560 subjects in about 30 clinical centers across the US, Canada, and Europe. The study is being overseen by Vastrax, Inc., the world’s leading full-service vascular clinical research organization (CRO).

The NeuroVasc ENVI™-SR is a next generation clot retrieval device for use in patients experiencing acute ischemic stroke. NeuroVasc ENVI™-SR was developed from the start as a stent-retriever, and the unique articulating segmental design allows the device to remain open under tension. The NeuroVasc ENVI™-SR was developed with the support of physicians from Canada, China, Japan, France, the United Kingdom, and the United States. It has received CE Mark and is currently under investigation in China. The NeuroVasc Envi™-SR is an investigational device, limited by federal (or United States) law to investigational use.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy